Table 5
Open in new tab

The baseline characteristic and outcome of patients with mitral regurgitation improvement as compared with those with not changed or worsened mitral regurgitation after 12 months of cardiac resynchronization therapy

MR improvement ≥1° at 12 months (n= 227)P value (within group)No change in MR at 12 months (n= 219)P value (within group)MR worsening ≥1° at 12 months (n= 60)P value (within group)P value (between groups)
Prevalence of CAD36%36%42%0.581
MR at baseline
 Mild/moderate101/308 (33%)159/308 (52%)48/308 (16%)<0.0001
 Advanced (MR 3–4)126/199 (63%)61/199 (31%)12/199 (6%)<0.001
NYHA class
 Baseline3.04 ± 0.49<0.0012.96 ± 0.52<0.0012.96 ± 0.49<0.0010.348
 12 month2.29 ± 0.642.35 ± 0.652.54 ± 0.630.054
QRS (ms)
 Baseline161 ± 35<0.001162 ± 32<0.0001162 ± 370.0120.986
 12 month141 ± 23144 ± 21147 ± 400.283
LVEDD (mm/m)
 Baseline69 ± 100.03268 ± 11<0.000170 ± 10<0.0010.321
 12 month58 ± 2259 ± 2366 ± 170.032
LVESD (mm/m)
 Baseline56 ± 110.08955 ± 11<0.000159 ± 12<0.0010.288
 12 month42 ± 2145 ± 2153 ± 180.204
LVEF (%)
  Baseline24 ± 8<0.00124 ± 7<0.000123 ± 70.3880.283
 12 month30 ± 1129 ± 1223 ± 80.001
LA area (mm2)
 Baseline48 ± 80.00547 ± 90.77748 ± 71.0000.343
 12 month46 ± 847 ± 749 ± 70.073
RV dilatation
 Baseline29%32%32%0.969
 12 month26%32%42%0.714
RV dysfunction—mild/moderate:
 Baseline45%41%35%0.004
 12 month30%38%45%0.806
RV dysfunction—Severe
 Baseline07%04%15%0.002
 12 month06%06%13%0.526
Atrial fibrillation—paroxysmal:
 Baseline65%62%56%0.032
 12 month69%63%54%0.025
Atrial fibrillation—LSPersistent
 Baseline35%38%44%0.024
 12 month31%37%46%0.085
MR improvement ≥1° at 12 months (n= 227)P value (within group)No change in MR at 12 months (n= 219)P value (within group)MR worsening ≥1° at 12 months (n= 60)P value (within group)P value (between groups)
Prevalence of CAD36%36%42%0.581
MR at baseline
 Mild/moderate101/308 (33%)159/308 (52%)48/308 (16%)<0.0001
 Advanced (MR 3–4)126/199 (63%)61/199 (31%)12/199 (6%)<0.001
NYHA class
 Baseline3.04 ± 0.49<0.0012.96 ± 0.52<0.0012.96 ± 0.49<0.0010.348
 12 month2.29 ± 0.642.35 ± 0.652.54 ± 0.630.054
QRS (ms)
 Baseline161 ± 35<0.001162 ± 32<0.0001162 ± 370.0120.986
 12 month141 ± 23144 ± 21147 ± 400.283
LVEDD (mm/m)
 Baseline69 ± 100.03268 ± 11<0.000170 ± 10<0.0010.321
 12 month58 ± 2259 ± 2366 ± 170.032
LVESD (mm/m)
 Baseline56 ± 110.08955 ± 11<0.000159 ± 12<0.0010.288
 12 month42 ± 2145 ± 2153 ± 180.204
LVEF (%)
  Baseline24 ± 8<0.00124 ± 7<0.000123 ± 70.3880.283
 12 month30 ± 1129 ± 1223 ± 80.001
LA area (mm2)
 Baseline48 ± 80.00547 ± 90.77748 ± 71.0000.343
 12 month46 ± 847 ± 749 ± 70.073
RV dilatation
 Baseline29%32%32%0.969
 12 month26%32%42%0.714
RV dysfunction—mild/moderate:
 Baseline45%41%35%0.004
 12 month30%38%45%0.806
RV dysfunction—Severe
 Baseline07%04%15%0.002
 12 month06%06%13%0.526
Atrial fibrillation—paroxysmal:
 Baseline65%62%56%0.032
 12 month69%63%54%0.025
Atrial fibrillation—LSPersistent
 Baseline35%38%44%0.024
 12 month31%37%46%0.085

Abbreviations as in Tables 1 and 2.

Table 5
Open in new tab

The baseline characteristic and outcome of patients with mitral regurgitation improvement as compared with those with not changed or worsened mitral regurgitation after 12 months of cardiac resynchronization therapy

MR improvement ≥1° at 12 months (n= 227)P value (within group)No change in MR at 12 months (n= 219)P value (within group)MR worsening ≥1° at 12 months (n= 60)P value (within group)P value (between groups)
Prevalence of CAD36%36%42%0.581
MR at baseline
 Mild/moderate101/308 (33%)159/308 (52%)48/308 (16%)<0.0001
 Advanced (MR 3–4)126/199 (63%)61/199 (31%)12/199 (6%)<0.001
NYHA class
 Baseline3.04 ± 0.49<0.0012.96 ± 0.52<0.0012.96 ± 0.49<0.0010.348
 12 month2.29 ± 0.642.35 ± 0.652.54 ± 0.630.054
QRS (ms)
 Baseline161 ± 35<0.001162 ± 32<0.0001162 ± 370.0120.986
 12 month141 ± 23144 ± 21147 ± 400.283
LVEDD (mm/m)
 Baseline69 ± 100.03268 ± 11<0.000170 ± 10<0.0010.321
 12 month58 ± 2259 ± 2366 ± 170.032
LVESD (mm/m)
 Baseline56 ± 110.08955 ± 11<0.000159 ± 12<0.0010.288
 12 month42 ± 2145 ± 2153 ± 180.204
LVEF (%)
  Baseline24 ± 8<0.00124 ± 7<0.000123 ± 70.3880.283
 12 month30 ± 1129 ± 1223 ± 80.001
LA area (mm2)
 Baseline48 ± 80.00547 ± 90.77748 ± 71.0000.343
 12 month46 ± 847 ± 749 ± 70.073
RV dilatation
 Baseline29%32%32%0.969
 12 month26%32%42%0.714
RV dysfunction—mild/moderate:
 Baseline45%41%35%0.004
 12 month30%38%45%0.806
RV dysfunction—Severe
 Baseline07%04%15%0.002
 12 month06%06%13%0.526
Atrial fibrillation—paroxysmal:
 Baseline65%62%56%0.032
 12 month69%63%54%0.025
Atrial fibrillation—LSPersistent
 Baseline35%38%44%0.024
 12 month31%37%46%0.085
MR improvement ≥1° at 12 months (n= 227)P value (within group)No change in MR at 12 months (n= 219)P value (within group)MR worsening ≥1° at 12 months (n= 60)P value (within group)P value (between groups)
Prevalence of CAD36%36%42%0.581
MR at baseline
 Mild/moderate101/308 (33%)159/308 (52%)48/308 (16%)<0.0001
 Advanced (MR 3–4)126/199 (63%)61/199 (31%)12/199 (6%)<0.001
NYHA class
 Baseline3.04 ± 0.49<0.0012.96 ± 0.52<0.0012.96 ± 0.49<0.0010.348
 12 month2.29 ± 0.642.35 ± 0.652.54 ± 0.630.054
QRS (ms)
 Baseline161 ± 35<0.001162 ± 32<0.0001162 ± 370.0120.986
 12 month141 ± 23144 ± 21147 ± 400.283
LVEDD (mm/m)
 Baseline69 ± 100.03268 ± 11<0.000170 ± 10<0.0010.321
 12 month58 ± 2259 ± 2366 ± 170.032
LVESD (mm/m)
 Baseline56 ± 110.08955 ± 11<0.000159 ± 12<0.0010.288
 12 month42 ± 2145 ± 2153 ± 180.204
LVEF (%)
  Baseline24 ± 8<0.00124 ± 7<0.000123 ± 70.3880.283
 12 month30 ± 1129 ± 1223 ± 80.001
LA area (mm2)
 Baseline48 ± 80.00547 ± 90.77748 ± 71.0000.343
 12 month46 ± 847 ± 749 ± 70.073
RV dilatation
 Baseline29%32%32%0.969
 12 month26%32%42%0.714
RV dysfunction—mild/moderate:
 Baseline45%41%35%0.004
 12 month30%38%45%0.806
RV dysfunction—Severe
 Baseline07%04%15%0.002
 12 month06%06%13%0.526
Atrial fibrillation—paroxysmal:
 Baseline65%62%56%0.032
 12 month69%63%54%0.025
Atrial fibrillation—LSPersistent
 Baseline35%38%44%0.024
 12 month31%37%46%0.085

Abbreviations as in Tables 1 and 2.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close